XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Subsequent Event
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
Subsequent Event

12. Subsequent Event

In July 2023, the Company expanded its current licensing agreement for trofinetide with Neuren to acquire rights to the drug outside of North America as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591. Under the terms of the expanded agreement, Neuren will receive an upfront payment of $100.0 million and is eligible to receive up to the following additional milestone payments based on the achievement of certain development and sales milestones (in thousands):

 

 

Trofinetide

 

 

NNZ-2591

 

Development milestones

 

$

 

 

$

15,000

 

First commercial sale milestones

 

 

 

 

 

 

North America

 

 

 

 

 

40,000

 

Europe

 

 

45,000

 

 

 

45,000

 

Japan

 

 

18,750

 

 

 

18,750

 

Sales milestones

 

 

 

 

 

 

North America

 

 

 

 

 

350,000

 

Europe

 

 

170,000

 

 

 

170,000

 

Japan

 

 

110,000

 

 

 

110,000

 

Rest of World

 

 

82,500

 

 

 

82,500

 

Total milestone payments

 

$

426,250

 

 

$

831,250

 

 

In addition, the Company will be required to pay Neuren tiered royalties from the mid-teens to low-twenties percent of trofinetide net sales outside of North America. Percentage royalties related to NNZ-2591 net sales are identical to the trofinetide in each of North America and outside North America.